By Fineline Cube B&K Corporation Limited (HKG: 2396) announced the completion of patient enrollment in its Phase II clinical trial evaluating Pro-101-2, a recombinant human PDGF-BB (rhPDGF-BB) drug, for the treatment of diabetic foot ulcers (DFU).
Development Milestone
| Component | Detail |
|---|---|
| Company | B&K Corporation Limited (founded 2012) |
| Trial Status | Phase II patient enrollment completed |
| Lead Asset | Pro-101-2 – recombinant human PDGF-BB (rhPDGF-BB) |
| Indication | Diabetic foot ulcers |
| Therapeutic Focus | Multi-functional wound healing therapies |
| Core Technology | Platelet-derived growth factor (PDGF) platform |
| Announcement Date | 13 Jul 2026 |
Company Profile & Intellectual Property
B&K Corporation – Wound Healing Specialist
- Founded: 2012
- Primary Focus: Novel protein drugs for wound healing applications
- Technology Platform: Platelet-derived growth factor (PDGF) therapeutics
- Intellectual Property Portfolio:
- 13 issued patents
- 19 pending patent applications
- Core Product Pipeline:
- Pro-101-1: rhPDGF-BB for burns/scalds treatment
- Pro-101-2: rhPDGF-BB for diabetic foot ulcers treatment
Market Context – Diabetic Foot Ulcers
- Patient Population: Affects 15-25% of diabetes patients globally; approximately 230 million people with diabetes worldwide
- Clinical Challenge: Chronic non-healing wounds with high amputation risk; current standard of care shows limited efficacy
- Economic Burden: DFU treatment costs exceed $9-13 billion annually in the U.S. alone
- Unmet Need: More effective growth factor therapies required to accelerate healing and reduce complications
Competitive Landscape & Strategic Position
| Aspect | Details |
|---|---|
| Existing Competition | Regranex (becaplermin) – original rhPDGF-BB approved in 1997; limited market penetration due to safety concerns and cost |
| B&K’s Differentiation | Next-generation rhPDGF-BB formulation with potential improved safety profile and manufacturing efficiency |
| Market Opportunity | Global wound care market projected to reach $25+ billion by 2028, with DFU representing premium segment |
| Regulatory Pathway | Phase II data will inform Phase III design; potential for accelerated approval based on unmet medical need |
Strategic Implications
- Pipeline Progression: Successful Phase II completion represents critical de-risking milestone for lead asset
- Commercial Potential: DFU indication offers premium pricing opportunity in specialized wound care market
- Platform Validation: Success of Pro-101-2 would validate B&K’s PDGF platform for broader wound healing applications
- Geographic Expansion: Initial focus on China market with potential for international partnerships post-approval
- Investor Value: Completion of enrollment reduces development timeline uncertainty and positions company for next financing round or partnership discussions
The wound healing space continues to attract significant interest from both specialty pharmaceutical companies and large-cap players seeking differentiated biologic therapies for chronic conditions.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and commercial potential for Pro-101-2. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech